Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.51 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 5/20 | 0.45 |
| ▸ | CTSS | P25774 | 5/20 | 0.45 |
| ▸ | CTSB | P07858 | 4/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CTSK | P43235 | 5/20 | 0.43 |
| ▸ | KYNU | Q16719 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ELANE | P08246 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18261538 | 0.87 | SYK (0.48) | SYKCTRB1SMN1; SMN2CTSLCTSS | |
| SCHEMBL5435292 | 0.82 | SYK (0.50) | SYKCTRB1SMN1; SMN2CTSLCTSS | |
| SCHEMBL4829896 | 0.80 | CTRB1 (0.68) | SYKCTRB1SMN1; SMN2CTSLCTSS | |
| SCHEMBL3291883 | 0.80 | CTSS (0.59) | SYKCTRB1SMN1; SMN2CTSLCTSS | |
| SCHEMBL27269043 | 0.80 | CTSS (0.59) | SYKCTRB1SMN1; SMN2CTSLCTSS | |
| SCHEMBL3294963 | 0.80 | CTSS (0.59) | SYKCTRB1SMN1; SMN2CTSLCTSS | |
| SCHEMBL7568024 | 0.80 | SYK (0.55) | SYKCTRB1CTSLCTSSCTSB | |
| SCHEMBL7568028 | 0.80 | SYK (0.55) | SYKCTRB1CTSLCTSSCTSB | |
| SCHEMBL17646287 | 0.80 | SYK (0.47) | SYKCTRB1SMN1; SMN2CTSLCTSS | |
| SCHEMBL2636259 | 0.78 | SYK (0.64) | SYKCTRB1CTSLCTSSCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107635586-B | Antibody-drug conjugates (ADC) of KSP inhibitors with aglycosylated anti-TWEAKR antibodies | 拜耳医药股份有限公司 | 2021-09-24 | — | — | CN | disclosed |
| CN-106163568-B | Antibody Drug Conjugates (ADC) containing spindle Kinesin (KSP) | 拜耳制药股份公司 | 2021-03-23 | — | — | CN | disclosed |
| US-7446102-B2 | Antibacterial amide macrocycles IV | AICURIS GMBH & CO. KG (DE) | 2008-11-04 | — | — | US | disclosed |
| US-20080076745-A1 | ANTIBACTERIAL AMIDE MACROCYCLES IV | AICURIS GMBH & CO. KG (DE) | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076745-A1 | ANTIBACTERIAL AMIDE MACROCYCLES IV | NOD2, AAAS, AADAC | SYK 3060/4885CTRB1 606/4885SMN1; SMN2 3609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.